Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland

International Journal of Cancer

Volumn 119, Issue 2, 2006, Pages 472-475

  Steffen, Jan ^a   Nowakowska, Dorota ^a   Niwińska, Anna ^a   Czapczak, Dorota ^a   Kluska, Anna ^a   Pia̧tkowska, Magdalena ^a   Wiśniewska, Alicja ^a   Paszko, Zygmut ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

657del5 mutation; BRCA1; Breast cancer risk; NBS1

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RISK; EXON; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GERM LINE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NBS1 GENE; ONCOGENE; POLAND; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL CYCLE PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INCIDENCE; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; POLAND; RISK FACTORS;

EID: 33745225487     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21853     Document Type: Article

References (39)

1. Saar K, Chrzanowska KH, Stumm M, Jung M, Nurnberg G, Wienker TF, Seemanova E, Wegner RD, Reis A, Sperling K. The gene for the ataxia-telangiectasia variant, Nijmegen breakage syndrome, maps to a 1-cM interval on chromosome 8p21. Am J Hum Genet 1997;60:605-10.
2. Cerosaletti KM, Lange E, Stringham HM, Weemaes CM, Smeets D, Solder B, Belohradsky BH, Taylor AM, Karnes P, Eliott A, Komatsu K, Gatti RA, et al. Fine localization of the Nijmegen breakage syndrome gene to 8q21: evidence for a common founder haplotype. Am J Hum Genet 1998;63:125-34.
3. Weemaes CM, Husting TW, Scheres JM, van Munster PJ, Bakkeren JA, Taalman RD. A new chromosomal instability disorder. The Nijmegen breakage syndrome. Acta Paediatr Scand 1981;70:557-64.
4. van der Burgt I, Chrzanowska KH, Smeets D, Weemaes C. Nijmegen breakage syndrome. J Med Genet 1996;33:153-6.
5. Varon R, Seemanova E, Chrzanowska K, Hnateyko O, Piekutowska-Abramczuk D, Krajewska-Walasek M, Sykut-Cegielska J, Sperling K, Reis A. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slavic populations. Eur J Hum Genet 2000;8:900-2.
6. The International Nijmegen Breakage Syndrome Study Group. Nijmegen breakage syndrome. Arch Dis Child 2000;82:400-6
7. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, Beckmann G, Seemanowa E, Cooper PR, Nowak NJ, Stumm M, Weemaes CM, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998;93:467-76.
8. Digweed M, Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 2004;3:1207-17.
9. Matsuura S, Kobayashi J, Tauchi H, Komatsu K. Nijmegen breakage syndrome and DNA double strand break repair by NBS1 complex. Adv Biophys 2004;38:65-80.
10. Iijima K, Komatsu K, Matsuura S, Tauchi H. The Nijmegen breakage syndrome gene and its role in genome stability. Chromosoma 2004;113:53-61.
11. Abraham RT, Tibbetts RS. Cell biology. Guiding ATM to broken DNA. Science 2005;308:510-11.
12. Ziólkowska I, Mosor M, Nowak J. The frequency of heterozygous mutation 657del5 carriers of the NBS1 gene in the Wielkopolska voivodship. J Appl Genet, in press.
13. Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, Nowakowska D, Rubach M, Kosakowska E, Ruka W, Nowecki Z, Rutkowski P, et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 2004;111:67-71.
14. Dȩbniak T, Górski B, Cybulski C, Jakubowska A, Kurzawski G, Lener M, Mierzejewski M, Masojć B, Mȩdrek K, Kladny J, Zaluga E, Maleszka R, et al. Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin. Melanoma Res 2003; 13:365-70.
15. Cybulski C, Górski B, Dȩbniak T, Gliniewicz B, Mierzejewski M, Masojć B, Jakubowska A, Matyjasik J, Zlowocka E, Sikorski A, Narod SA, Lubiński J. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004;64:1215-19.
16. Varon R, Reis A, Henze G, von Einsiedel HG, Sperling K, Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res 2001;61: 3570-2.
17. Taylor GM, O'Brien HP, Greaves MF, Ravetto PF, Eden OB. Letters to the editor. Cancer Res 2003;63:6563-4.
18. Correspondence re: Varon R, et al. Mutation in the Nijmegen breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia. Cancer Res 2001;61:3570-3572.
19. Seemanova E, Sperling K, Neitzel H, Varon R, Hadac J, Butova O, Schrock E, Seeman P, Digweed M. Nijmegen Breakage syndrome (NBS) with immunological abnormalities and without chromosomal instability. J Med Genet, in press..
20. Górski B, Dȩbniak T, Masojć B, Mierzejewski M, Mȩdrek K, Cybulski C, Jakubowska A, Kurzawski G, Chosia M, Scott R, Lubinski J. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 2003;106:379-81.
21. Buslov KG, Iyevleva AG, Chekmariova EV, Suspitsin EN, Togo AV, Kuligina ESh, Sokolenko AP, Matsko DE, Turkevich EA, Lazareva YR, Chagunava OL, Bit-Sava EM, et al. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer 2005;114:585-9.
22. Carlomagno F, Chang-Claude J, Dunning AM, Ponder BA. Determination of the frequency of the common 657del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. Genes Chromosomes Cancer 1999;25:393-5.
23. Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bȩbenek M, Sorokin D, Fiszer-Maliszewska Ł, Haus O, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004;110:683-6.
24. Struewing JP, Hange P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with the 185delAG and 5382insC mutations of BRCA1 and the 6174delT mutation of BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
25. Cerosaletti KM, Morrison VA, Sabath DE, Willerford DM, Concannon P. Mutations and molecular variants of the NBS1 gene in non-Hodgkin lymphoma. Genes Chromosomes Cancer 2002;35:282-6.
26. Cavaciuti E, Lauge A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D, Andrieu N. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer 2005;42:1-9.
27. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. Cancer risk and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22.
28. King MC, Marks JH, Mandell JB for the New York Breast Cancer Study Group. Breast and ovarian cancer risk due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6
29. Wojciechowska U, Ditkowska J, Tarkowski W, Zatoński W. Cancer in Poland in 2002. The M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 2004.
30. Kluska A, Wojciechowska-Ła̧cka A, Pia̧tkowska M, Nowakowska D, Balabas A, Rachtan J, Molong I, Skasko E, Niwińska A, Kwiatkowska E, Steffen J. Preliminary evaluation of the frequencies and types of BRCA1 germline mutations among patients with familial and sporadic breast and ovarian cancers from 3 regions of Poland (in polish). Nowotwory J Oncol 2005;55 (Suppl 2)27 (Abstract). Special issue on IV Polish Conference on Diagnosis and Treatment of Breast Cancer.
31. Dumon-Jones V, Frappart PO, Tong WM, Sajithlal G, Hulla W, Schmid G, Herceg Z, Digweed M, Wang ZQ. Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis. Cancer Res 2003;63:7263-9.
32. Seidemann K, Tiemann M, Henze G, Sauerbrey A, Muller S, Reiter A. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999;33:536-44.
33. Distel L, Neubauer S, Varon R, Holler W, Grabenbauer G. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol 2003;41:44-8.
34. Bakhshi S, Cerosaletti KM, Concannon P, Bawle EV, Fontanesi J, Gatti RA, Bhambhani K. Medulloblastoma with adverse reaction to radiation therapy in Nijmegen breakage syndrome. J Pediatr Hematol Oncol 2003;25:248-51.
35. Meyer S, Kingston H, Taylor AM, Byrd PJ, Last JI, Brennan BM, Trueman S, Kelsey A, Taylor GM, Eden OB. Rhabdomyosarcoma in Nijmegen breakage syndrome: strong association with perianal primary site. Cancer Genet Cytogenet 2004;154:169-74.
36. Robinson JG, Lu L, Dixon K, Bissler JJ. DNA lesion-specific colocalization of the Mre11/Rad50/Nbs1 (MRN) complex and replication protein A (RPA) to repair foci. J Biol Chem 2005;280:12927-34.
37. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20:6597-606.
38. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1 defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91.
39. Wojciechowska-Ła̧cka A, Markowska J, Skasko E, Kruczek A, Steffen J. Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report). Eur J Gynaec Oncol 2002;20:21-4.